利福平耐药实时荧光定量核酸扩增技术在肺结核临床路径中的应用
Applicative value of gene Xpert MTB/RIF for the rapid detection of pulmonary tuberculosis in the clinical pathway

DOI: 10.6040/j.issn.1671-7554.0.2018.152

Keywords: 耐多药肺结核,结核分枝杆菌,利福平耐药实时荧光定量核酸扩增技术,临床路径,
Gene Xpert mycobacterium tuberculosis DNA and resistance to rifampicin assay,Multi-drug resistant tuberculosis,Clinical pathway,Mycobacterium tuberculosis

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	陈利民, 柴志凯, 范月玲, 等. 山西省实施新型结核病防治服务模式效果评价[J]. 中国药物与临床, 2017, 17(2): 285-287.
[2]	张玉华, 张国钦, 钟达, 等. 应用Xpert MTB/RIF法对我国肺结核诊断及利福平耐药检测的Meta分析[J]. 现代预防医学, 2017, 44(12): 2116-2119, 2130.
[3]	Naik-Mathuria BJ, Rosenfeld EH, Gosain A, et al. Proposed clinical pathway for nonoperative management of high-grade pediatric pancreatic injuries based on a multicenter analysis: a pediatric trauma society collaborative[J]. J Trauma Acute Care Surg, 2017, 83(4): 589-596.
[4]	肖和平, 方勇. 多学科协作开启结核病防治新时代[J]. 中华结核和呼吸杂志, 2017, 40(5): 321-322.
[5]	Mindru R, Spinu V, Popescu O, et al. LPA or GeneXpert in the diagnosis of multidrug-resistant tuberculosis[J]. Pneumologia, 2016, 65(2): 76-80.
[6]	何坤,夏勇,袁国丹.Xpert MTB/RIF技术在早期诊断耐药结核中的应用研究[J]. 重庆医学, 2017, 26: 3707-3708.
[7]	王黎霞. 结核分枝杆菌药物敏感性实验标准化操作程序及质量保证手册[M]. 北京: 人民卫生出版社, 2013: 140.
[8]	Kaur R, Jindal N, Arora S, et al. Epidemiology of rifampicin resistant tuberculosis and common mutations in rpoB gene of mycobacterium tuberculosis: a retrospective study from six districts of punjab(India)using Xpert MTB/RIF assay[J]. J Lab Physicians, 2016, 8(2): 96-100.
[9]	Ueda A, Saito T, Ueda M, et al. Introduction and PDCA-Management of a liaison-clinical pathway with cancer patients after a curative operation[J]. Gan To Kagaku Ryoho, 2015, 42(10): 1197-1201.
[10]	van der Kolk M, van den Boogaard M, Becking-Verhaar F, et al. Implementation and evaluation of a clinical pathway for pancreaticoduodenectomy procedures: a prospective cohort study[J]. J Gastrointest Surg, 2017, 21(9): 1428-1441.
[11]	喻国旗, 雷明智, 魏怡, 等. 2004-2015年中国大陆地区肺结核流行的时空分布特征[J]. 现代预防医学, 2017, 44(20): 3649-3654. YU Guoqi, LEI Mingzhi, WEI Yi, et al. Characteristic of spatial-temporal distribution of pulmonary tuberculosis in mainland China from 2004 to 2015[J]. Modern Preventive Medicine, 2017, 44(20): 3649-3654.
[12]	吴腾燕, 刘飞鹰, 曹云飞, 等. 广西各级结核病防治机构人力资源的现状分析[J]. 现代预防医学, 2013, 40(13): 2448-2450, 2457. WU Tengyan, LIU Feiying, CAO Yunfei, et al. Analysis on the current situation of human resource in control and treatment organizations for tuberculosis in Guangxi[J]. Modern Preventive Medicine, 2013, 40(13): 2448-2450, 2457.
[13]	Héquet D, Huchon C, Baffert S, et al. Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators[J]. Br J Cancer, 2017, 116(11): 1394-1401.
[14]	Bryan MA, Desai AD, Wilson L, et al. Association of bronchiolitis clinical pathway adherence with length of stay and costs[J]. Pediatrics, 2017, 139(3): 34-32.
[15]	Furuhata H, Araki K, Ogawa T, et al. Effect on completion of clinical pathway for Improving clinical indicator: cases of hospital stay, mortality rate, and comprehensive-volume ratio[J]. J Med Syst, 2017, 41(12): 206-208.
[16]	Yerrabothala S, Talebian L, Klinker K, et al. Extracorporeal photopheresis for graft versus host disease: identifying a clinical pathway and associated resource utilization[J]. J Clin Apher, 2017, 83(4): 589-596.
[17]	Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis[J]. Lancet Respir Med, 2015, 3(6): 451-461.
[18]	Rutman L, Klein EJ, Brown JC, et al. Clinical pathway produces sustained Improvement in acute gastroenteritis care[J]. Pediatrics, 2017, 140(4): 89-93.
[19]	路阳, 李中凯, 陆晨, 等. 县级医院推行临床路径管理障碍分析和对策研究[J]. 中国卫生质量管理, 2016, 23(1): 22-26. LU Yang, LI Zhongkai, LU Chen, et al. Obstacles analysis and countermeasures of clinical pathway implementation in county hospitals[J]. Chinese Health Quality Management, 2016, 23(1): 22-26.
[20]	洪小丹, 林美娥, 梁玲飞. 临床护理路径用于后腹腔镜肾癌根治术的效果评价[J]. 浙江医学, 2015, 37(2): 166-168.
[21]	丁丽萍, 朱婧, 姚炯.临床路径变异因素的原因探讨[J]. 中国病案, 2015, 16(3): 22-24. DING Liping, ZHU Jing, YAO Jiong. Reason exploration of the variation of clinical pathways[J]. Chinese Medical Record, 2015, 37(2): 166-168.
[22]	苏俊华, 黄山, 余婷婷. 耐多药结核分枝杆菌92株对二线抗结核药耐药情况分析[J].实用医技杂志, 2016, 23(6): 581-583. SU Junhua, HUANG Shan, YU Tingting. Analysis of resistance to second-line drugs in 92 strains of multidrug resistance mycobacterium tuberculosis[J]. Journal of Practical Medical Techniques, 2016, 23(6): 581-583.
[23]	Rufai SB, Singh A, Kumar P, et al. Performance of Xpert MTB/RIF assay in diagnosis of pleural tuberculosis by use of pleural fluid samples[J]. J Clin Microbiol, 2015, 53(11): 363-368.

Full-Text